Infant Bacterial Therapeutics AB (publ) (STO: IBT.B)

Sweden flag Sweden · Delayed Price · Currency is SEK
100.00
+1.00 (1.01%)
Aug 30, 2024, 5:29 PM CET
20.19%
Market Cap 1.35B
Revenue (ttm) 69.00K
Net Income (ttm) -142.27M
Shares Out 13.47M
EPS (ttm) -10.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 14,745
Open 99.20
Previous Close 99.00
Day's Range 98.20 - 101.50
52-Week Range 70.80 - 135.00
Beta 1.13
Analysts n/a
Price Target n/a
Earnings Date Nov 14, 2024

About IBT.B

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies `to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 8
Stock Exchange Nasdaq Stockholm
Ticker Symbol IBT.B
Full Company Profile

Financial Performance

News

There is no news available yet.